J Neurol Surg A Cent Eur Neurosurg 2018; 79(02): 130-138
DOI: 10.1055/s-0037-1606354
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Deep Brain Stimulation in Patients with Parkinson's Disease: Effect on Psychiatric Symptoms and Quality of Life

Elisa Seijo Zazo
1   Psychiatry Department, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
,
Fernando Seijo Fernandez
2   Neurosurgery Department, Medical Center of Asturias, Oviedo, Spain
,
Elena Santamarta Liebana
3   Radiology Department, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
,
Antonio Saiz Ayala
3   Radiology Department, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
,
Beatriz Lozano Aragoneses
4   Neurophysiology Department, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
,
Jose Maria Torres Campa
2   Neurosurgery Department, Medical Center of Asturias, Oviedo, Spain
,
Paz Garcia Portilla
5   Psychiatry Department, Medical Center of Asturias, Oviedo, Spain
,
Marco Alvarez Vega
6   Department of Neurosurgery, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
› Author Affiliations
Further Information

Publication History

06 December 2016

27 June 2017

Publication Date:
29 September 2017 (online)

Abstract

Background and Study Aims To determine the effect on psychiatric symptoms and quality of life in 30 patients with Parkinson's disease (PD) treated with deep brain stimulation (DBS) of both subthalamic nuclei (STN) after 1 year of follow-up.

Material and Method We conducted a prospective 1-year follow-up study with a baseline assessment before and 6 and 12 months after surgery. The following were used as assessment instruments: the Bech-Rafaelsen Melancholia Scale (MES), the Bech-Rafaelsen Mania Scale (MAS), the Beck Scale for Suicidal Ideation (SSI), the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the Oviedo Sleep Questionnaire (OSQ), the 36-Item Short Form Health Survey (SF-36), the Unified Parkinson's Disease Rating Scale (UPDRS), the dose of levodopa, and the active contact stereotactic coordinates.

Results We recorded a clinical improvement between baseline with medication use (ON medication) and the results obtained at 6 and 12 months with medication use and stimulation (ON stimulation, ON medication) in MES and OSQ (p < 0.0001) and in SF-36 (p < 0.005). No changes were observed in MAS and SSI. There was a clinical improvement between baseline with ON medication and the results obtained at 12 months with ON stimulation, ON medication in Y-BOCS (p < 0.04). Also, there was a 53.3% reduction in levodopa at 6 months and a 54.7% reduction at 12 months after surgery (p < 0.0001). There was an improvement between baseline with OFF medication and the results obtained at 6 and 12 months OFF medication, ON stimulation (p < 0.0001) in UPDRS-III. There were no statistically significant differences between the initial and final active contact coordinates, or between stimulation parameters.

Conclusions DBS of the STN in patients with PD is associated with an improvement in psychiatric (affective and sleep-wake cycle) symptoms, clinical motor symptoms, and quality of life at 1 year after surgery.

 
  • References

  • 1 Schoenberg BS. Descriptive epidemiology of Parkinson's disease: disease distribution and hypothesis formulation. Adv Neurol 1987; 45: 277-283
  • 2 Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M. Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis 2012; 2012: 198316
  • 3 Aarsland D, Pedersen KF, Ehrt U, Bronnick K, Gjerstad MD, Larsen JP. Neuropsychiatric and cognitive symptoms in Parkinson disease [in Norwegian]. Tidsskr Nor Laegeforen 2008; 128 (18) 2072-2076
  • 4 Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009; 24 (15) 2175-2186
  • 5 Weaver FM, Follett K, Stern M. , et al; CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301 (01) 63-73
  • 6 Deuschl G, Schüpbach M, Knudsen K. , et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 2013; 19 (01) 56-61
  • 7 Ferreira JJ, Katzenschlager R, Bloem BR. , et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20 (01) 5-15
  • 8 Odin P, Ray Chaudhuri K, Slevin JT. , et al; National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord 2015; 21 (10) 1133-1144
  • 9 Carron R, Chabardès S, Hammond C. Mechanisms of action of high-frequency deep brain stimulation. A review of the literature and current concepts. Neurochirurgie 2012; 58 (04) 209-217
  • 10 Parsons TD, Rogers SA, Braaten AJ, Woods SP, Tröster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006; 5 (07) 578-588
  • 11 Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat Disord 2006; 12 (05) 265-272
  • 12 Voon V, Krack P, Lang AE. , et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008; 131 (Pt 10): 2720-2728
  • 13 Witt K, Daniels C, Volkmann J. Factors associated with neuropsychiatric side effects after STN-DBS in Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (Suppl. 01) S168-S170
  • 14 Seijo F, Alvarez de Eulate Beramendi S, Santamarta Liébana E. , et al. Surgical adverse events of deep brain stimulation in the subthalamic nucleus of patients with Parkinson's disease. The learning curve and the pitfalls. Acta Neurochir (Wien) 2014; 156 (08) 1505-1512 ; discussion 1512
  • 15 Bech P, Rafaelsen OJ. The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale. Acta Psychiatr Scand 1980; 62 (S285): 128-132
  • 16 Bech P, Rafaelsen OJ, Kramp P, Bolwig TG. The mania rating scale: scale construction and inter-observer agreement. Neuropharmacology 1978; 17 (06) 430-431
  • 17 Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol 1979; 47 (02) 343-352
  • 18 Goodman WK, Price LH, Rasmussen SA. , et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46 (11) 1006-1011
  • 19 Bobes J, González MP, Sáiz PA. , et al. Propiedades psicométricas del cuestionario oviedo de sueño. Psicothema 2000; 12: 107-112
  • 20 Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30 (06) 473-483
  • 21 Fahn S, Elton RL. & UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M. , eds. Recent Developments in Parkinson's Disease. Vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987: 153-164 , 293–304
  • 22 Seijo F, Saiz A, Lozano B. , et al. Neuromodulation of the posterolateral hypothalamus for the treatment of chronic refractory cluster headache: Experience in five patients with a modified anatomical target. Cephalalgia 2011; 31 (16) 1634-1641
  • 23 Manual de Codificación. CIE 10 ES Diagnósticos. Unidad Técnica de Codificación CIE 10 ES. Madrid, Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2016
  • 24 DSM IV TR. Manual Diagnóstico y Estadístico de los Trastornos Mentales. Barcelona, Spain: Masson; 2001: 1088
  • 25 Burkhard PR, Vingerhoets FJ, Berney A, Bogousslavsky J, Villemure JG, Ghika J. Suicide after successful deep brain stimulation for movement disorders. Neurology 2004; 63 (11) 2170-2172
  • 26 Doshi PK, Chhaya N, Bhatt MH. Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 2002; 17 (05) 1084-1085
  • 27 Funkiewiez A, Ardouin C, Caputo E. , et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75 (06) 834-839
  • 28 Houeto JL, Mallet L, Mesnage V. , et al. Subthalamic stimulation in Parkinson disease: behavior and social adaptation. Arch Neurol 2006; 63 (08) 1090-1095
  • 29 Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 2010; 6 (09) 487-498
  • 30 Jaafari N, Giré P, Houeto JL. Deep brain stimulation, Parkinson's disease and neuropsychiatric complications [in French]. Presse Med 2009; 38 (09) 1335-1342
  • 31 Bronstein JM, Tagliati M, Alterman RL. , et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011; 68 (02) 165
  • 32 Follett KA, Weaver FM, Stern M. , et al; CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362 (22) 2077-2091
  • 33 Gan J, Xie-Brustolin J, Mertens P. , et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: three years follow-up. J Neurol 2007; 254 (01) 99-106
  • 34 Okun MS, Fernandez HH, Wu SS. , et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009; 65 (05) 586-595
  • 35 Voon V, Kubu C, Krack P, Houeto JL, Tröster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21 (Suppl. 14) S305-S327
  • 36 Chopra A, Tye SJ, Lee KH. , et al. Underlying neurobiology and clinical correlates of mania status after subthalamic nucleus deep brain stimulation in Parkinson's disease: a review of the literature. J Neuropsychiatry Clin Neurosci 2012; 24 (01) 102-110
  • 37 Shon YM, Lee KH, Goerss SJ. , et al. High frequency stimulation of the subthalamic nucleus evokes striatal dopamine release in a large animal model of human DBS neurosurgery. Neurosci Lett 2010; 475 (03) 136-140
  • 38 Appleby BS, Duggan PS, Regenberg A, Rabins PV. Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: a meta-analysis of ten years' experience. Mov Disord 2007; 22 (12) 1722-1728
  • 39 Woods SP, Fields JA, Tröster AI. Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a critical review. Neuropsychol Rev 2002; 12 (02) 111-126
  • 40 Lilleeng B, Dietrichs E. Unmasking psychiatric symptoms after STN deep brain stimulation in Parkinson's disease. Acta Neurol Scand Suppl 2008; 188: 41-45
  • 41 Alegret M, Junqué C, Valldeoriola F, Vendrell P, Martí MJ, Tolosa E. Obsessive-compulsive symptoms in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70 (03) 394-396
  • 42 Fontaine D, Mattei V, Borg M. , et al. Effect of subthalamic nucleus stimulation on obsessive-compulsive disorder in a patient with Parkinson disease. Case report. J Neurosurg 2004; 100 (06) 1084-1086
  • 43 Kopell BH, Greenberg B, Rezai AR. Deep brain stimulation for psychiatric disorders. J Clin Neurophysiol 2004; 21 (01) 51-67
  • 44 Mallet L, Mesnage V, Houeto JL. , et al. Compulsions, Parkinson's disease, and stimulation. Lancet 2002; 360 (9342): 1302-1304
  • 45 Antonini A, Landi A, Mariani C, DeNotaris R, Pezzoli G. Deep brain stimulation and its effect on sleep in Parkinson's disease. Sleep Med 2004; 5 (02) 211-214
  • 46 Hjort N, Østergaard K, Dupont E. Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord 2004; 19 (02) 196-199
  • 47 Mehta SH, Morgan JC, Sethi KD. Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectr 2008; 13 (03) (Suppl. 04) 6-11
  • 48 Li D, Cao C, Zhang J, Zhan S, Chen S, Sun B. Subthalamic nucleus deep brain stimulation for Parkinson's disease: 8 years of follow-up. Transl Neurodegener 2013; 2 (01) 11
  • 49 Lyons KE, Pahwa R. Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease. J Neurosurg 2005; 103 (02) 252-255
  • 50 Daniels C, Krack P, Volkmann J. , et al. Is improvement in the quality of life after subthalamic nucleus stimulation in Parkinson's disease predictable?. Mov Disord 2011; 26 (14) 2516-2521
  • 51 Wang X, Chang C, Geng N. , et al. Long-term effects of bilateral deep brain stimulation of the subthalamic nucleus on depression in patients with Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (08) 587-591
  • 52 Funkiewiez A, Ardouin C, Krack P. , et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003; 18 (05) 524-530
  • 53 Kleiner-Fisman G, Herzog J, Fisman DN. , et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006; 21 (Suppl. 14) S290-S304
  • 54 Wodarg F, Herzog J, Reese R. , et al. Stimulation site within the MRI-defined STN predicts postoperative motor outcome. Mov Disord 2012; 27 (07) 874-879
  • 55 Welter ML, Schüpbach M, Czernecki V. , et al. Optimal target localization for subthalamic stimulation in patients with Parkinson disease. Neurology 2014; 82 (15) 1352-1361
  • 56 Geevarghese R, O'Gorman Tuura R, Lumsden DE, Samuel M, Ashkan K. Registration accuracy of CT/MRI fusion for localisation of deep brain stimulation electrode position: an imaging study and systematic review. Stereotact Funct Neurosurg 2016; 94 (03) 159-163
  • 57 Paek SH, Yun JY, Song SW. , et al. The clinical impact of precise electrode positioning in STN DBS on three-year outcomes. J Neurol Sci 2013; 327 (1–2): 25-31
  • 58 Kondziolka D, Dempsey PK, Lunsford LD. , et al. A comparison between magnetic resonance imaging and computed tomography for stereotactic coordinate determination. Neurosurgery 1992; 30 (03) 402-406 ; discussion 406–407
  • 59 O'Gorman RL, Jarosz JM, Samuel M, Clough C, Selway RP, Ashkan K. CT/MR image fusion in the postoperative assessment of electrodes implanted for deep brain stimulation. Stereotact Funct Neurosurg 2009; 87 (04) 205-210
  • 60 Thani NB, Bala A, Swann GB, Lind CR. Accuracy of postoperative computed tomography and magnetic resonance image fusion for assessing deep brain stimulation electrodes. Neurosurgery 2011; 69 (01) 207-214 ; discussion 214
  • 61 Schaltenbrand G, Warren W. Atlas for Stereotaxy of the Human Brain. Stuttgart, Germany: Thieme; 1977
  • 62 Godinho F, Thobois S, Magnin M. , et al. Subthalamic nucleus stimulation in Parkinson's disease : anatomical and electrophysiological localization of active contacts. J Neurol 2006; 253 (10) 1347-1355
  • 63 Hamel W, Fietzek U, Morsnowski A. , et al. Subthalamic nucleus stimulation in Parkinson's disease: correlation of active electrode contacts with intraoperative microrecordings. Stereotact Funct Neurosurg 2003; 80 (1–4): 37-42
  • 64 Voges J, Volkmann J, Allert N. , et al. Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson disease: correlation of therapeutic effect with anatomical electrode position. J Neurosurg 2002; 96 (02) 269-279
  • 65 Weise LM, Seifried C, Eibach S. , et al. Correlation of active contact positions with the electrophysiological and anatomical subdivisions of the subthalamic nucleus in deep brain stimulation. Stereotact Funct Neurosurg 2013; 91 (05) 298-305
  • 66 Salvador-Aguiar C, Menéndez-Guisasola L, Blázquez-Estrada M, Fernández-González F, Seijo-Fernández F. Psychiatric symptoms of Parkinson's disease following deep brain stimulation surgery on the subthalamic nucleus [in Spanish]. Rev Neurol 2004; 39 (07) 651-655
  • 67 Frankemolle AM, Wu J, Noecker AM. , et al. Reversing cognitive-motor impairments in Parkinson's disease patients using a computational modelling approach to deep brain stimulation programming. Brain 2010; 133 (Pt 3): 746-761
  • 68 Lalys F, Haegelen C, Mehri M, Drapier S, Vérin M, Jannin P. Anatomo-clinical atlases correlate clinical data and electrode contact coordinates: application to subthalamic deep brain stimulation. J Neurosci Methods 2013; 212 (02) 297-307
  • 69 Eisenstein SA, Koller JM, Black KD. , et al. Functional anatomy of subthalamic nucleus stimulation in Parkinson disease. Ann Neurol 2014; 76 (02) 279-295
  • 70 Aviles-Olmos I, Kefalopoulou Z, Tripoliti E. , et al. Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry 2014; 85 (12) 1419-1425
  • 71 Zaidel A, Spivak A, Grieb B, Bergman H, Israel Z. Subthalamic span of beta oscillations predicts deep brain stimulation efficacy for patients with Parkinson's disease. Brain 2010; 133 (Pt 7): 2007-2021
  • 72 Garcia-Garcia D, Guridi J, Toledo JB, Alegre M, Obeso JA, Rodríguez-Oroz MC. Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization. J Neurosurg 2016; 125 (05) 1068-1079
  • 73 Abulseoud OA, Kasasbeh A, Min HK. , et al. Stimulation-induced transient nonmotor psychiatric symptoms following subthalamic deep brain stimulation in patients with Parkinson's disease: association with clinical outcomes and neuroanatomical correlates. Stereotact Funct Neurosurg 2016; 94 (02) 93-101
  • 74 Frank MJ, Samanta J, Moustafa AA, Sherman SJ. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007; 318 (5854): 1309-1312
  • 75 Cozac VV, Ehrensperger MM, Gschwandtner U. , et al. Older candidates for subthalamic deep brain stimulation in Parkinson's disease have a higher incidence of psychiatric serious adverse events. Front Aging Neurosci 2016; 8: 132
  • 76 Schuepbach Wm, Rau J, Knudsen K. , et al. Neurostimulation for Parkinson's diseases with early motor complications. N Engl J Med 2013; 368 (07) 610-622